# May Measurement Month 2019: an analysis of blood pressure screening results from Malaysia 

Yook Chin Chia ${ }^{1,2 *}$, Navin Kumar Devaraj ${ }^{3,4}$, Jack Bee Chook ${ }^{1}$, Ming Tsuey Chew ${ }^{1}$, Pei Boon Ooi ${ }^{1}$, Mohazmi Mohamed ${ }^{2,5}$, Nani Draman ${ }^{6}$, Wei Leik $\mathrm{Ng}^{2}$, Abdul Hafiz Mohamad Gani ${ }^{7}$, Nagammai Thiagarajan ${ }^{8}$, Zafferina Zulghaffar ${ }^{9}$, Thomas Beaney ${ }^{10,11}$, Emily Day ${ }^{10}$, Neil R. Poulter ${ }^{10}$, and Siew Mooi Ching ${ }^{3,4}$<br>${ }^{1}$ Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, 5 Jalan Universiti, Bandar Sunway, 47500 Selangor, Malaysia<br>${ }^{2}$ Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Lembah Pantai, 50603 Kuala Lumpur, Malaysia<br>${ }^{3}$ Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia<br>${ }^{4}$ Malaysian Research Institute on Ageing, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia<br>${ }^{5}$ Student Health Unit, University of Malaya Medical Centre, Jalan Universiti, Lembah Pantai, 59100 Wilayah Persekutuan Kuala Lumpur, Malaysia<br>${ }^{6}$ Department of Family Medicine, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, 15200 Kota Bahru, Kelantan, Malaysia<br>${ }^{7}$ Mahmoodiah Government Health Clinic, JKR 6274, Jalan Mahmoodiah, 80000 Johor Bahru, Johor, Malaysia<br>${ }^{8}$ Kuala Lumpur Government Health Clinic, Jalan Temerloh, Titiwangsa, 53200 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia<br>${ }^{9}$ Sungai Manila Government Health Clinic, D/A32 Pejabat Kesihatan Kawasan Sandakan, Tingkat 6, Rumah Persekutuan Sandakan, 90500 Sandakan, Sabah, Malaysia<br>${ }^{10}$ Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK<br>${ }^{11}$ Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London W6 8RP, UK

## KEYWORDS

Hypertension; prevalence;
Blood pressure;
Screening;
Treatment;
Control;
Malaysia;
awareness

Despite hypertension remaining the leading cause of death worldwide, awareness of hypertension and its control rate is still suboptimal in Malaysia. This study aims to determine the proportion of both diagnosed and undiagnosed hypertension, awareness and its control rate during the yearly May Measurement Month (MMM) campaign that has been coordinated by the International Society of Hypertension. Participants aged $\geq 18$ years were recruited at various screening sites namely universities, health facilities, shopping malls, and other sites. Participant's socio-demographic, environmental, and lifestyle data were captured using a questionnaire. Three blood pressure (BP) readings as well as anthropometric measurements were obtained from all participants. The mean of the second and third BP readings was used in analyses. Hypertension was defined as a systolic BP $\geq 140 \mathrm{mmHg}$ and/or diastolic BP $\geq 90 \mathrm{mmHg}$ or taking antihypertensive medication. A total of 3062 participants were recruited. The proportion with hypertension in our study was $18.7 \%(n=572)$. The proportion who were aware of their BP status was $63.2 \%$. More than half ( $57.2 \%$ ) of the hypertensives were on antihypertensive medication and $70.3 \%$ of those treated were

[^0]controlled. In conclusion, in this BP screening campaign, one in five were hypertensive with almost two thirds aware of their hypertensive status. BP control among those who are taking medications was high at $70 \%$ but under $60 \%$ of hypertensives were on treatment. Hypertension screening programmes are important to promote awareness and control of hypertension as well as to reduce the devastating complications associated with this disorder.

## Introduction

In the latest 2019 National Health and Morbidity Survey, the overall prevalence of hypertension among adults aged 18 years and above was $30.0 \%$, while it was $30.3 \%$ in the 2015 survey. ${ }^{1,2}$ Non-communicable diseases including hypertension are the leading cause of death worldwide and in Malaysia, account for $67 \%$ of premature mortality, and over $70 \%$ of disease burden in $2014 .{ }^{1}$ Cardiovascular diseases alone accounted for $35 \%$ of deaths in Malaysia. ${ }^{3}$ Malaysia was invited by the International Society of Hypertension in its inaugural worldwide blood pressure (BP) screening campaign in conjunction with World Hypertension Day in 2017 and has been participating in the May Measurement Month (MMM) campaign yearly.

As compared to the screening campaign in 2017, in 2018, there was a fall in the proportion of hypertension from $32.4 \%$ to $28.9 \%{ }^{4,5}$ Another major finding in the 2018 study was that the proportion of hypertensives aware of having hypertension was $76.3 \%$ which was much higher than the National Health and Morbidity Survey (NHMS) 2015 rate of $43.2 \%{ }^{2,5}$

In 2019, we once again participated in the MMM2019 BP screening campaign due to our high prevalence of hypertension and high mortality due to cardiovascular diseases. ${ }^{1-3}$

## Methods

This MMM 2019 study in Malaysia was led by Prof Dr Yook Chin Chia, assisted by Assoc Prof Dr Siew Mooi Ching and Dr Navin Kumar Devaraj. Ethical clearance was obtained from the National Medical Research Register (NMRR-19-113746868). There were 18 screening sites with two in East Malaysia and the rest in West Malaysia. A total of 40 investigators were involved. Investigators were trained electronically through e-mails and WhatsApp as most had participated in MMM 2017 and 2018 previously. The study was mainly self-funded by the individual investigators with around USD500 sponsorship given by the Malaysian Society of Hypertension to reimburse certain transportation and printing costs. Recruiting of participants were carried out in various locations including shopping malls, health campaigns, theme parks, universities, as well as health clinics and a hospital. Screening started on 1 May 2019 and ended on 31 July 2019. Omron HEM-7121, JPN1 and HBP-1300, Rossmax X1, Microlife B-A2-Basic and Beurer BM-28 digital BP sets were used for this study. BP was measured three times in a seated position on the upper arm using these
validated BP machines by various professional bodies (International Society of Hypertension, International Society of Hypertension and British Society of Hypertension) according to the standard MMM prototocol. ${ }^{6}$ The mean of the second and third readings was used in analyses.

Hypertension was defined as systolic BP $\geq 140 \mathrm{mmHg}$ or diastolic $\mathrm{BP} \geq 90 \mathrm{mmHg}$ or on treatment for hypertension. ${ }^{6}$ Data collection was collected via a self-administered hard copy questionnaire and captured in an Excel format. Local data were cleaned by Dr Navin Kumar Devaraj and analysed centrally by MMM project team. Multiple imputation was performed for second or third BP readings that were missing. ${ }^{6}$

## Results

There were 3062 participants. The mean age of the participants was $35.9 \pm 15.5$ years with the majority of the participants being female ( $63.7 \%$ ). The highest race represented in this study was Malays ( $60.6 \%$ ) with least in the others ethnic group category (5.4\%).

There were only $214(7.0 \%)$ of participants who had never had their BP measured before. One hundred and eighty-five (6.0\%) and 118 (3.9\%) were on statins and aspirin, respectively. A total of 2094 participants out of the total of 3062 had three sitting BP measurements while the rest had one or two $B P$ measurements.

The proportion of participants with hypertension in our study was $18.7 \%(n=572)$. The proportion of hypertensives who were aware of their BP status was $63.2 \%$. More than half ( $57.2 \%$ ) of the hypertensives were on medications and $70.3 \%$ among those treated were controlled (Table 1). Hence, 35 out of $362(9.7 \%)$ who were aware of their hypertension diagnosis were not on medication while $90.3 \%$ (327/362) were on medications.

## Discussion

In MMM 2019, the proportion of participants with hypertension was $18.7 \%$ which is much lower than that of the proportion of $32.4 \%$ in 2017 and $28.9 \%$ in $2018 .{ }^{4,5}$ This low proportion when compared to the national prevalence of $30.0 \%$ in 2019 could be a result of the participants who took part in this study being younger (mean age in this study was 35.9 years vs. 39.8 years in 2018 and 45.4 in 2017). What this tells us is that an opportunistic BP screening campaign may have advantages such as allowing more younger people to come forward to be screened for hypertension. This is important as published literatures have reported low hypertension diagnosis prevalence in younger people meeting

Table 1 Total participants and proportions with hypertension, awareness, on medication, and with controlled BP

| Total participants | Number with hypertension ( $n$, \%) |  | Number of hypertensives aware ( $n$, \%) |  | Number of hypertensives on medication ( $n, \%$ ) |  | Number of those on medication with controlled BP ( $n$, \%) |  | Number of all hypertensives with controlled BP ( $n, \%$ ) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No |
| 3062 | 572, 18.7\% | 2490, 81.3\% | 362, 63.2\% | 210, 36.8\% | 327, $57.2 \%$ | 245, 42.8\% | 230, $70.3 \%$ | 97, $29.7 \%$ | 230, 40.2\% | 342, 59.8\% |

the criteria for diagnosis. ${ }^{7,8}$ The proportion who were aware of their hypertension status in this year's screening remains high at 63.2\%. The awareness in the previous year was also high at $76.3 \%{ }^{5}$ Our lower awareness this year could have been contributed to the larger proportion of younger participants who are known to have lower awareness. ${ }^{9}$ Nevertheless, the awareness reported this year is still better than the national awareness of $37.5 \%$ reported several years ago. ${ }^{9}$ This could be a benefit of continuous BP screening which could potentially increase awareness rates.

The strength of our study is a large sample size and multiple sites of screening throughout the country including both rural and urban areas although clearly by design, it was not a nationally representative sample.

In conclusion, in this BP screening campaign, the proportion of hypertension was lower compared to previous MMM campaigns with high awareness of hypertension status. BP control among those who are taking medications was good but hypertension treatment rates were suboptimal.

## Acknowledgements

We would like to thank all investigators, volunteers and also the participants of this study. We would also like to thank the Malaysian Society of Hypertension-Sunway University Young Investigators Network for their assistance in data collection. Data of this study is available on writing formally to the corresponding author.

## Funding

We would like to thank the Malaysian Society of Hypertension for partially funding this study.

Conflict of interest: none declared.

## References

1. Institute for Public Health (IPH). The National Health and Morbidity Survey 2019 (NHMS 2019). Vol. I: Non-Communicable Diseases: Risk factors and other health problems. Kuala Lumpur: Ministry of Health Malaysia; 2019. http://iku.moh.gov.my/images/IKU/Document/ REPORT/NHMS2019/Report_NHMS2019-NCD_v2.pdf (date last accessed 25 March 2021).
2. Institute for Public Health (IPH). National Health and Morbidity Survey 2015 (NHMS 2015). Vol. II: Non-Communicable Diseases, Risk Factors \& Other Health Problem. Kuala Lumpur: Ministry of Health Malaysia; 2015. http://www.iku.gov.my/images/IKU/Document/ REPORT/nhmsreport2015vol2.pdf (date last accessed 25 March 2021).
3. World Health Organization-Noncommunicable Diseases (NCD) Country Profiles, 2018.https://www.who.int/nmh/countries/mys_en.pdf (26 November 2020)
4. Chia YC, Ching SM, Chew BN, Devaraj NK, Mohd Yusof SS, Tay CL, Kang PS, Verna Lee KM, Kong SZ, Teoh SW, Nurjasmine AJ, Poulter NR, Thomas B, Xin X. May measurement month 2017 blood pressure screening: findings from Malaysia-South-East Asia and Australasia. Eur Heart J Suppl 2019;21:D77-D79.
5. Chia YC, Ching SM, Devaraj NK, Chew BN, Ooi PB, Mohamed M, Othman AS, Kang PS, Husin HS, Mohamad Gani AH, Hamid D, Thomas B, Ster AC, Poulter NR, Xin X. May Measurement Month 2018: an analysis of blood pressure screening results from Malaysia. Eur Heart J Suppl 2020;22:H83-H85.
6. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, Cro S, Diaz A, Damasceno A, Espeche W, Jose AP, Khan N, Kokubo Y, Maheshwari A, Marin MJ, More A, Neupane D, Nilsson P, Patil M, Prabhakaran D, Ramirez A, Rodriguez P, Schlaich M, Steckelings UM, Tomaszewski M, Unger T, Wainford R, Wang J, Williams B, Poulter NR; on behalf of MMM Investigators. May Measurement Month 2019: the Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension 2020;76:333-341.
7. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-2050.
8. Daugherty SL, Masoudi FA, Ellis JL, Ho PM, Schmittdiel JA, Tavel HM, Selby JV, O’Connor PJ, Margolis KL, Magid DJ. Age-dependent gender differences in hypertension management. J Hypertens 2011; 29: 1005-1011.
9. Ab Majid NL, Omar MA, Khoo YY, Mahadir Naidu B, Ling MYJ, Rodzlan Hasani WS, Mat Rifin H, Abd Hamid HA, Robert Lourdes TG, Mohd Yusoff MF. Prevalence, awareness, treatment and control of hypertension in the Malaysian population: findings from the national health and morbidity survey 2006-2015. J Hum Hypertens 2018;32:617-624.

[^0]:    *Corresponding author. Tel: +603 74918622, Ext: 7410, Fax: +603 56358633, Email: ycchia@sunway.edu.my

